Fundraising Fox
XenoTherapeutics
Enfield, US · Founded 2019 · Delaware corporation
Find your way into XenoTherapeutics
Sign up to see every warm intro you have to XenoTherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the XenoTherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
XenoTherapeutics develops regenerative medicine therapies derived from genetically engineered pigs as a living donor source, aiming to replace human cadaver tissue. Its first product, realSKIN, is a living skin transplant intended to support healing after severe injury.
Founders & leadership
XenoTherapeutics was founded in 2019 by Paul Holzer.
PH
Paul HolzerFounder
JA
Jon AdkinsPresident & Executive Director | Co-FounderJon Adkins has worked in orthopedics, biologics, and regenerative medicine prior to co-founding XenoTherapeutics. At the company, he focuses on capital strategy, regulatory pathway development, and operational execution for realSKIN, a living skin transplant derived from genetically engineered pigs.
Reported raises · per SEC filings
Form D private placements$2M disclosed across 2 rounds · 2019–2021
▶$1.3MraisedApr 2021 · 8 investors · BiotechnologyRule 506(b)
▶$1.3MraisedApr 2021 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Krysta MoultonExecutive Officer, Director
- Paul HolzerExecutive Officer, Director
- Jon AdkinsExecutive Officer, Director
- Offering amount
- $8M
- Amount sold
- $1.3M
- Minimum investment
- $25K
- Proceeds to insiders
- $1.5M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$700.1KraisedJun 2019 · 5 investors · BiotechnologyRule 506(b)
▶$700.1KraisedJun 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Krysta MoultonExecutive Officer, Director
- Paul HolzerExecutive Officer, Director
- Jon AdkinsExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $700.1K
- Proceeds to insiders
- $600K
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Xenon PharmaceuticalsXenon is a neuroscience-focused biopharmaceutical company that discovers and develops ion channel modulators as therapeutics for neurological and psychiatric disorders. Its pipeline includes a Phase 3 program in epilepsy and depression for its lead candidate azetukalner, along with early-stage pain programs targeting sodium and potassium channels.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as XenoTherapeutics.
In the news
Frequently asked questions
- What does XenoTherapeutics do?
- XenoTherapeutics develops regenerative medicine therapies derived from genetically engineered pigs as a living donor source, aiming to replace human cadaver tissue. Its first product, realSKIN, is a living skin transplant intended to support healing after severe injury.
- Who founded XenoTherapeutics?
- XenoTherapeutics was founded by Paul Holzer in 2019.
- How much funding has XenoTherapeutics raised?
- XenoTherapeutics has disclosed $2M raised across 2 rounds.
- Where is XenoTherapeutics headquartered?
- XenoTherapeutics is headquartered in Enfield, US.